Literature DB >> 9121809

Competitive and non-competitive NMDA antagonists block the development of antinociceptive tolerance to morphine, but not to selective mu or delta opioid agonists in mice.

E J Bilsky1, C E Inturrisi, W Sadée, V J Hruby, F Porreca.   

Abstract

N-Methyl-D-aspartate (NMDA) receptor antagonists have been shown to block the development of antinociceptive tolerance to morphine. Assessment of the effects of NMDA antagonists on development of antinociceptive tolerance to selective opioid mu (mu) and delta (delta) agonists, however, has not been reported. In these experiments, selective mu and delta receptor agonists, and morphine, were repeatedly administered to mice either supraspinally (i.c.v.) or systemically (s.c.), alone or after pretreatment with systemic NMDA antagonists. Antinociception was evaluated using a warm-water tail-flick test. Repeated i.c.v. injections of mu agonists including morphine, fentanyl, [D-Ala2, NMePhe4, Gly-ol]enkephalin (DAMGO) and Tyr-Pro-NMePhe-D-Pro-NH2 (PL017) or [D-Ala2, Glu4]deltorphin, a delta agonist, or s.c. injections of morphine or fentanyl, produced antinociceptive tolerance as shown by a significant rightward displacement of the agonist dose-response curves compared to controls. Single injections or repeated administration of MK801 (a non-competitive NMDA antagonist) or LY235959 (a competitive NMDA antagonist) at the doses employed in this study did not produce behavioral toxicity, antinociception or alter the acute antinociceptive effects of the tested opioid agonists. Consistent with previous reports, pretreatment with MK801 or LY235959 (30 min prior to agonist administration throughout the tolerance regimen) prevented the development of antinociceptive tolerance to i.c.v. or s.c. morphine. Neither NMDA antagonist, however, affected the development of antinociceptive tolerance to i.c.v. fentanyl, DAMGO, or [D-Ala2, Glu4]deltorphin. Additionally, MK801 pretreatment did not affect the development of antinociceptive tolerance to i.c.v. PL017 or to s.c. fentanyl. Further, MK801 pretreatment also did not affect the development of tolerance to the antinociception resulting from a cold-water swim-stress episode, previously shown to be a delta-opioid mediated effect. These data lead to the suggestion that the mechanisms of tolerance to receptor selective mu and delta opioids may be regulated differently from those associated with morphine. Additionally, these findings emphasize that conclusions reached with studies employing morphine cannot always be extended to 'opiates' in general.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9121809     DOI: 10.1016/s0304-3959(96)03185-5

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  18 in total

1.  The mu-opioid receptor and the NMDA receptor associate in PAG neurons: implications in pain control.

Authors:  María Rodríguez-Muñoz; Pilar Sánchez-Blázquez; Ana Vicente-Sánchez; Esther Berrocoso; Javier Garzón
Journal:  Neuropsychopharmacology       Date:  2011-08-03       Impact factor: 7.853

2.  Effects of manipulating progesterone and NMDA receptors in the ventral tegmental area for lordosis of hamsters and rats.

Authors:  Cheryl A Frye; Jennifer Marrone; Alicia Walf
Journal:  Psychopharmacology (Berl)       Date:  2008-06-29       Impact factor: 4.530

3.  Neurophysiology of Cancer Pain: From the Laboratory to the Clinic.

Authors: 
Journal:  Curr Rev Pain       Date:  1999

Review 4.  Pathophysiology of medication overuse headache: insights and hypotheses from preclinical studies.

Authors:  Ian D Meng; David Dodick; Michael H Ossipov; Frank Porreca
Journal:  Cephalalgia       Date:  2011-03-28       Impact factor: 6.292

5.  Selective agonist of group II glutamate metabotropic receptors, LY354740, inhibits tolerance to analgesic effects of morphine in mice.

Authors:  P Popik; E Kozela; A Pilc
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

Review 6.  Glutamate receptors and nociception: implications for the drug treatment of pain.

Authors:  M E Fundytus
Journal:  CNS Drugs       Date:  2001-01       Impact factor: 5.749

7.  Continuous intracerebroventricular infusion of the competitive NMDA receptor antagonist, LY235959, facilitates escalation of cocaine self-administration and increases break point for cocaine in Sprague-Dawley rats.

Authors:  Richard M Allen; Kristina A Uban; Elizabeth M Atwood; David S Albeck; Dorothy J Yamamoto
Journal:  Pharmacol Biochem Behav       Date:  2007-07-21       Impact factor: 3.533

8.  NMDA receptor antagonists inhibit opiate antinociceptive tolerance and locomotor sensitization in rats.

Authors:  Ian A Mendez; Keith A Trujillo
Journal:  Psychopharmacology (Berl)       Date:  2007-11-10       Impact factor: 4.530

9.  G-protein receptor kinase 3 (GRK3) influences opioid analgesic tolerance but not opioid withdrawal.

Authors:  Gregory W Terman; Wenzhen Jin; Young-Pyo Cheong; Janet Lowe; Marc G Caron; Robert J Lefkowitz; Charles Chavkin
Journal:  Br J Pharmacol       Date:  2003-12-08       Impact factor: 8.739

10.  Blockade of NMDA receptors prevents analgesic tolerance to repeated transcutaneous electrical nerve stimulation (TENS) in rats.

Authors:  Priyanka M Hingne; Kathleen A Sluka
Journal:  J Pain       Date:  2007-12-03       Impact factor: 5.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.